annb0t
Top 20
Immutep Limited
Oral presentation will detail new clinical data for eftilagimod alpha in combination with pembrolizumab in 1st line NSCLC patients from TACTI-002/KEYNOTE-798 Phase II trial
Media Release
SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a late-breaking abstract ...
>>> Read more: Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
Oral presentation will detail new clinical data for eftilagimod alpha in combination with pembrolizumab in 1st line NSCLC patients from TACTI-002/KEYNOTE-798 Phase II trial
Media Release
SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutepâ or âthe Companyâ), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a late-breaking abstract ...
>>> Read more: Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
